BioSmart바이오스마트

BioSmart is a small, diversified Korean firm with thin margins, a recent swing back to modest profit, and heavy borrowings.

BioSmart runs several unrelated businesses, including smart cards, pharmaceuticals, liquor payment services, heavy electrical and copper products, and book publishing. Trailing twelve-month revenue is about ₩563B with operating income of about ₩28B and net income of about ₩13B as of H1 2026. The shares trade at ₩2,740, well below the 52-week high of ₩6,930, and the company pays no dividend.

What stands out

• Trailing net margin is 2.4% and operating margin is 5%, so profitability is thin relative to revenue.
• 2024 net income was only about ₩0.1B, while 2025 net income recovered to about ₩9.0B, showing volatile earnings.
• Borrowings of about ₩90B exceed cash of about ₩38B, and trailing free cash flow is negative at about -₩22B.
• Valuation metrics are low, with a P/E of 5.1 and P/B of 0.5, while peers trade at much higher multiples.
• Foreign ownership rose from 6.9% to 7.4% over the past 60 days, and the 1-year share price return is -5.2%.

What to watch

• The next quarterly or annual results, to see whether margins and the recovery in net income hold.
• Whether negative free cash flow and debt levels improve, since liabilities are 74.9% of equity.
• Recent filings were mostly insider and 5%+ holding reports; the data does not explain their purpose, and no recent news headlines were available.